BigHat Biosciences is a biotechnology company that applies machine learning and high-throughput synthetic biology to the design and development of antibody therapies. Its work focuses on accelerating the discovery and optimization of antibody drugs with improved safety and efficacy profiles.
The company's central technical asset is the Milliner platform. This system integrates an advanced wet laboratory with machine learning algorithms specifically for therapeutic antibody engineering. A key operational capability of the platform is its throughput: it can synthesize, purify, and fully characterize hundreds of recombinant antibodies within a single weekly workcell cycle.
BigHat's work sits at the intersection of several technical domains, including machine learning, synthetic biology, and antibody engineering. The company operates within the biotechnology and pharmaceutical industries.
